Navigation

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201) [ID482]

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 and over and adults (review of TA133 and TA201)

Status: History
Expected date of issue: April 2013
Process: MTA
Topic area:
  • Respiratory
 

NICE project team

Executive Lead: Gillian Leng
Technical Lead: Richard Diaz
Communications manager: Katie Williamson
Project manager: Jeremy Powell
Top


 

Provisional schedule

Consultation on draft scope by stakeholders: 28 June 2011
Closing date for invited submissions / evidence submission: 12 January 2012
1st appraisal committee meeting: 03 July 2012
2nd appraisal committee meeting: 03 October 2012
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Novartis (omalizumab)

Patient/carer groups

  • Asthma UK

Professional groups

  • Association of Respiratory Nurse Specialists
  • British Society for Allergy & Clinical Immunology
  • British Thoracic Society
  • Primary Care Respiratory Society
  • Royal College of Nursing
  • Royal College of Paediatrics and Child Health
  • Royal College of Pathologists
  • Royal College of Physicians
  • Royal Pharmaceutical Society
  • United Kingdom Clinical Pharmacy Association

Others

  • Department of Health
  • Welsh Government

General

  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland
  • Medicines and Healthcare products Regulatory Agency

Comparator manufacturer(s)

  • None

Relevant research groups

  • MRC and Asthma UK Centre in Allergic Mechanisms of Asthma

Evidence Review Group

  • Health Technology Assessment Programme
  • NHS Centre for Reviews & Dissemination and Centre for Health Economics

Associated Guideline groups

Associated Public Health groups

  • tbc

Top


 

Project history

Date Update
30 July 2012 Following the first Committee meeting the Appraisal Committee has requested that additional information be collected and analyses undertaken by the Assessment Group. The second meeting has been delayed to allow this work to be completed.
Top


 

Key documents

This page was last updated: 23 April 2013

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.